In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Celgene licenses its d-methylphenidate to Novartis

Executive Summary

In exchange for $10mm up front, milestones of up to $100mm, plus funding of development and marketing, Novartis has licensed worldwide rights, excluding Canada, to Celgene's Phase III Attenade (d-methylphenidate) for use in attention deficit/attention deficit hyperactivity disorders. Celgene retains manufacturing rights and all rights in oncology.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Chiral Chemistry
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies